Last reviewed · How we verify

NCT03717974: HANDI@CCESS

Medico-economic Impact Evaluation in Telemedecine Follow-up in Complement of a Mobile Team in Patients With Neurological Disabilities (HANDI@CCESS)

Completed NA Last updated 11 February 2022
What this trial tests

NA trial testing Telemedecine follow-up after an intervention at home of the mobile team in Severe Neurological Disabilities in 80 participants. Completed in 25 January 2022.

Timeline
24 September 2018
Primary endpoint
22 November 2021
25 January 2022

Quick facts

Lead sponsorPôle Saint Hélier
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment80
Start date24 September 2018
Primary completion22 November 2021
Estimated completion25 January 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Pôle Saint Hélier

Who can join

18 and older, any sex, with Severe Neurological Disabilities. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Access to care for people with traumatic or degenerative neurological disabilities is a current public health concern. New technological tools such as telemedicine can bring expertise to the place of life of people while promoting the city-hospital link.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cost effectiveness of a telerehabilitation intervention vs home based care for adults with severe neurologic disability: A randomized clinical trial.
    Duruflé A, Le Meur C, Piette P, Fraudet B, et al · · 2023 · cited 9× · PMID 37545632 · DOI 10.1177/20552076231191001

Verify or expand the search:

Other Pôle Saint Hélier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing